Kinase Inhibitor News and Research RSS Feed - Kinase Inhibitor News and Research

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib. [More]
AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. [More]
Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9. [More]

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

... [More]

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

The Lancet Oncology has published results from the largest ever trial of a single melanoma treatment. The open label safety study was conducted to assess the tolerability of Zelboraf (vemurafenib), and featured 3,222 patients from across 44 countries.1 246 of these patients were from the UK. [More]
NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for patients with advanced non-squamous non-small-cell lung cancer, shows a Canadian analysis. [More]

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance. [More]
Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). [More]

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests. [More]
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013. [More]

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI). [More]

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Activation of the insulin-like growth factor 1 receptor plays a key role in acquired resistance to erlotinib in lung cancer with wild-type epidermal growth factor receptor, research suggests. [More]

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend. [More]

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. [More]
CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis. [More]

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer. [More]
ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients. [More]

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology. [More]

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. [More]
Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. [More]